



Evolve ETFs

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018

Annual Management Report of Fund Performance

This annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the investment fund. You can get a copy of the annual financial statements at your request, and at no cost, by calling 1-844-370-4884, by writing to us at Evolve Funds, 161 Bay Street, Suite 2700, Toronto, ON, M5J 2S1 or by visiting our website at [www.evolveetfs.com](http://www.evolveetfs.com) or SEDAR at [www.sedar.com](http://www.sedar.com). You may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018

---

## Investment Objective and Strategies

---

The Evolve Global Healthcare Enhanced Yield ETF (the "Fund") seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged (the "Benchmark"), or any successor thereto, while mitigating downside risk. The Fund invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the Manager. The level of covered call option writing may vary based on market volatility and other factors.

## Risk

---

There were no changes to the Fund over the period of this report that materially affected the level of risk associated with an investment in the Fund. Prospective investors should read the Fund's most recent prospectus and consider the description of risks contained therein.

## Results of Operations

---

For the year ended December 31, 2018, the non-hedged units returned 15.84% versus the Solactive Global Healthcare 20 Index return of 12.53%. The hedged units returned 2.07% versus the Solactive Global Healthcare 20 Canadian Dollar Index Hedged return of 1.59%. The difference in performance of the hedged units relative to its benchmark can be attributed primarily to management fees plus applicable sales taxes and to portfolio trading and hedging strategies. The difference in performance of the non-hedged units relative to its benchmark can be attributed primarily to management fees plus applicable sales taxes and to portfolio trading. Furthermore, the difference can also be attributed to the implementation of the call writing strategy where the Fund tend to outperform in flat or down markets and underperform during sharp market advances. This performance difference can be seen over the period the calls are written, typically with one to two months to expiry, and then resets when new option positions are established. Fund's net assets were \$3.404MM as at December 31, 2018.

## Portfolio Manager Commentary

---

The need for healthcare continued to rise as a result of the ageing population and increasing longevity, benefitting drug companies. Though volatile in line with the broad market, healthcare stocks performed well over the year, resulting in the fund generating a total return of 12.2%. As well, the fund's active covered call strategy neutralized the portfolio's volatility over the year.

In the US, after failing to repeal Obamacare, the Trump administration weakened it by cutting subsidies and halving the insurance enrollment period, while rolling out health plans with reduced benefits, negatively impacting individual drug and insurance costs.

Risks to the drug industry were exposed when the pharmaceutical and chemical giant, Bayer, lost 11% or \$20 billion of its market value in a single day, following an order by a California court to pay \$289 million in damages related to alleged cancer risks caused by its herbicide, Roundup. Incidentally, the number of U.S. lawsuits brought against Bayer, which acquired Monsanto, the maker of Roundup has jumped to about 8,000.

The best performing stocks in the portfolio for the year were Eli Lilly & Co., with a gain of 53%, followed by Merck & Co. which was up 52.5% and Abbott Laboratories 40.6%.

## Recent Developments

---

There are no known changes at this time to the investment strategy of the Fund or the Manager.

## Related Party Transactions

---

The Manager complies with its current policy and procedures regarding investments in related issuers and reports periodically to the Independent Review Committee.

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018

## Management Fees

The management fees are calculated based on 0.45% per annum of the average daily net asset value of the Fund. The fees are accrued daily and are generally paid monthly. For the period ended December 31, 2018, the Fund incurred \$12,614 in management fees. These management fees were received by Evolve Funds Group Inc. for the day-to-day operations of the fund, including managing the portfolio, maintaining portfolio systems used to manage the Fund, maintaining the www.evolveetfs.com website, and providing all other services including marketing and promotion.

## Administration fees

The administration fees are calculated based on 0.15% per annum of the average daily net asset value of the Fund. The fees are accrued daily and are generally paid monthly. For the period ended December 31, 2018, the Fund incurred \$4,205 in administration fees. These administration fees were received by Evolve Funds Group Inc. for the following operating expenses of the Fund including but not limited to: mailing and printing expenses for periodic reports to unitholders; fees payable to the index provider, Registrar and Transfer Agent and Custodian; any reasonable out of pocket expenses incurred by the Manager or its agents in connection with their ongoing obligations to the Fund; IRC committee member fees and expenses in connection with the IRC; expenses related to compliance with NI 81-107; fees and expenses relating to voting of proxies by a third party; insurance coverage for the members of the IRC; fees payable to the auditors and legal advisors of the Fund; regulatory filing, stock exchange and licensing fees and CDS fees; costs and expenses of complying with all applicable laws, regulations and policies, including expenses and costs incurred in connection with the continuous public filing requirements such as permitted prospectus preparation and filing expenses; and legal, accounting and audit fees and fees and expenses of the Trustee, Custodian and Manager which are incurred in respect of matters not in the normal course of the Fund's activities. The administration fee paid to the Manager by the Fund, in any particular period, be less than or exceed the operating expenses that the Manager incurs for that class.

## Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help readers understand the Fund's financial performance for the period indicated.

### The Fund's Net Assets Per Unit<sup>1</sup>

	December 31, 2018 (\$)	December 31, 2017 (\$)
For the periods ended:		
<b>Unhedged Units - Net Assets per Unit</b>		
Net Assets per Unit, beginning of period	19.02	19.80
<b>Increase (decrease) from operations:</b>		
Total revenue	0.60	0.05
Total expenses	(0.54)	(0.03)
Realized gains (losses)	(3.16)	0.02
Unrealized gains (losses)	3.51	(0.61)
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>0.41</b>	<b>(0.57)</b>
<b>Distributions:</b>		
From dividends	-	(0.01)
Return of capital	(0.87)	(0.14)
<b>Total annual distributions<sup>3</sup></b>	<b>(0.87)</b>	<b>(0.15)</b>
<b>Net Assets per Unit, end of period</b>	<b>21.10</b>	<b>19.02</b>

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018

## The Fund's Net Assets Per Unit<sup>1</sup> (cont'd)

	December 31, 2018 (\$)	December 31, 2017 (\$)
For the periods ended:		
<b>Hedged Units - Net Assets per Unit</b>		
Net Assets per Unit, beginning of period	19.28	19.73
<b>Increase (decrease) from operations:</b>		
Total revenue	0.51	0.06
Total expenses	(0.45)	(0.03)
Realized gains (losses)	0.68	(0.26)
Unrealized gains (losses)	(1.20)	(0.31)
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>(0.46)</b>	<b>(0.54)</b>
<b>Distributions:</b>		
From dividends	-	(0.00)
Return of capital	(0.87)	(0.15)
<b>Total annual distributions<sup>3</sup></b>	<b>(0.87)</b>	<b>(0.15)</b>
<b>Net Assets per Unit, end of period</b>	<b>18.79</b>	<b>19.28</b>

- 1 This information is derived from the Fund's audited annual financial statement as at December 31, 2018, and 2017. The Fund began operations on October 25, 2017.
- 2 Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the period.
- 3 Distributions were paid in cash or reinvested in additional units of the Fund, or both. Actual distributions may vary slightly owing to rounding.

## The Fund's Ratios/Supplemental Data

	December 31, 2018	December 31, 2017
For the periods ended:		
<b>Unhedged Units - Ratios/Supplemental Data</b>		
Total Net Asset Value (\$) <sup>4</sup>	1,055,018	1,902,143
Number of units outstanding <sup>4</sup>	50,000	100,000
Management expense ratio <sup>5</sup>	0.69%	0.67%
Trading expense ratio <sup>6</sup>	1.31%	0.14%
Portfolio turnover rate <sup>7</sup>	341.86%	1.44%
Net Asset Value per unit (\$)	21.10	19.02
Closing market price (\$)	21.07	19.11
<b>Hedged Units - Ratios/Supplemental Data</b>		
Total Net Asset Value (\$) <sup>4</sup>	2,349,306	1,445,902
Number of units outstanding <sup>4</sup>	125,000	75,000
Management expense ratio <sup>5</sup>	0.69%	0.66%
Trading expense ratio <sup>6</sup>	1.31%	0.14%
Portfolio turnover rate <sup>7</sup>	341.86%	1.44%
Net Asset Value per unit (\$)	18.79	19.28
Closing market price (\$)	18.80	19.34

- 4 This information is provided as at December 31, 2018 and December 31, 2017.
- 5 Management expense ratio ("MER") is based on total expenses plus harmonized sales tax (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset value during the period.
- 6 The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of average daily net assets during the period.
- 7 The Fund's portfolio turnover rate indicates how actively the Fund's portfolio manager trades its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the period. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018


## Past Performance

The performance information does not take into account sales, redemption, distribution, income taxes payable by any unitholder or other optional charges that, if applicable, would have reduced returns or performance. The performance information shown assumes that all distributions made by the investment Fund in the periods shown were reinvested in additional securities of the investment fund. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.


## Year-by-Year Returns

The bar chart below shows the Fund's annual performance for the periods shown. The chart shows, in percentage terms, how much an investment made in the Fund on the first day would have grown or decreased by the last day of the period.

### LIFE/B<sup>1</sup>



### LIFE<sup>2</sup>



1 The non-hedged class of the Fund effectively began operation on October 25, 2017.

2 The hedged class of the Fund effectively began operation on October 25, 2017.

## Summary of Investment Portfolio

### Top 25 Positions

Security	Percentage of Net Asset Value (%)
Merck & Company Inc.	5.7
Novo Nordisk A/S, ADR	5.5
Roche Holding AG, ADR	5.5
Abbott Laboratories	5.5
Eli Lilly & Company	5.4
Sanofi, ADR	5.3
Pfizer Inc.	5.3
Novartis AG, ADR	5.3
AbbVie Inc.	5.3
GlaxoSmithKline PLC, ADR	5.2
Danaher Corporation	5.2
Amgen Inc.	5.2
Johnson & Johnson	5.1
Thermo Fisher Scientific Inc.	5.1
AstraZeneca PLC, ADR	5.1
Medtronic PLC	5.1
Biogen Inc.	4.7

# Evolve Global Healthcare Enhanced Yield ETF

December 31, 2018

## Top 25 Positions (cont'd)

	Percentage of Net Asset Value (%)
Security	
Bristol-Myers Squibb Company	4.7
Gilead Sciences Inc.	4.4
Bayer AG, ADR	4.2
<b>Total</b>	<b>102.8</b>

## Industry Allocation

Portfolio by Category	Percentage of Net Asset Value (%)
<b>Equities</b>	
Health Care	102.8
Derivative Assets	0.3
Derivative Liabilities	(2.6)
Cash and Cash Equivalents	0.1
Other Assets, less Liabilities	(0.6)
<b>Total</b>	<b>100.0</b>

The summary of Investment Portfolio may change due to the ongoing portfolio transactions of the Fund. Updates are available quarterly by visiting our website at [www.evolveetfs.com](http://www.evolveetfs.com).



**Evolve ETFs**

**Evolve Global Healthcare Enhanced Yield ETF**